TY - GEN
T1 - Biophotonic platform for detection of hallmarks of Alzheimer's disease via combined microfluidics and nanofunctionalized fiber sensors
AU - Rivero, Desiree Santano
AU - Zu, Lijiao
AU - Xie, Jiwei
AU - Liu, Peng
AU - Zhang, Xuejun
AU - Shi, Lei
AU - Socorro Leránoz, Abián B.
AU - Matias, Ignacio R.
AU - Giannetti, Ambra
AU - Baldini, Francesco
AU - Santamaría, Enrique
AU - Fernández-Irigoyen, Joaquín
AU - Li, Kaiwei
AU - Bi, Wei
AU - van den Hove, Daniel
AU - Del Villar, Ignacio
AU - Guo, Tuan
AU - Chiavaioli, Francesco
N1 - Publisher Copyright:
© 2023 IEEE.
PY - 2023
Y1 - 2023
N2 - The emergence of Covid-19 pandemic has drawn large attention to vulnerable people affected by major diseases. According to the World Health Organization (WHO), more than 55 million people worldwide suffer from dementia. Alzheimer's disease (AD) is the predominant type of dementia, accounting for 60-70% of cases [1]. A long-standing challenge is to attain early diagnosis of AD hallmarks (tau protein, τP; amyloid beta, Aβ) by detecting them in biological fluids, thus avoiding the labor of specialized hospital personnel and the high cost of imaging examinations. Different biological fluids are being used to detect AD biomarkers, such as cerebrospinal fluid (CSF), serum, blood-plasma [2]. Biomarker level in CSF has been shown to increase in the very early stages of the disease where its elevated value makes higher the risk of a quicker development of AD dementia. Traditional methods for biomarker detection are mostly based on ELISA or mass spectrometry, which possess well-known disadvantages in comparison with electrochemical or optical approaches [3,4].
AB - The emergence of Covid-19 pandemic has drawn large attention to vulnerable people affected by major diseases. According to the World Health Organization (WHO), more than 55 million people worldwide suffer from dementia. Alzheimer's disease (AD) is the predominant type of dementia, accounting for 60-70% of cases [1]. A long-standing challenge is to attain early diagnosis of AD hallmarks (tau protein, τP; amyloid beta, Aβ) by detecting them in biological fluids, thus avoiding the labor of specialized hospital personnel and the high cost of imaging examinations. Different biological fluids are being used to detect AD biomarkers, such as cerebrospinal fluid (CSF), serum, blood-plasma [2]. Biomarker level in CSF has been shown to increase in the very early stages of the disease where its elevated value makes higher the risk of a quicker development of AD dementia. Traditional methods for biomarker detection are mostly based on ELISA or mass spectrometry, which possess well-known disadvantages in comparison with electrochemical or optical approaches [3,4].
UR - https://www.scopus.com/pages/publications/85175732597
U2 - 10.1109/CLEO/EUROPE-EQEC57999.2023.10231804
DO - 10.1109/CLEO/EUROPE-EQEC57999.2023.10231804
M3 - Conference contribution
AN - SCOPUS:85175732597
T3 - 2023 Conference on Lasers and Electro-Optics Europe and European Quantum Electronics Conference, CLEO/Europe-EQEC 2023
BT - 2023 Conference on Lasers and Electro-Optics Europe and European Quantum Electronics Conference, CLEO/Europe-EQEC 2023
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 2023 Conference on Lasers and Electro-Optics Europe and European Quantum Electronics Conference, CLEO/Europe-EQEC 2023
Y2 - 26 June 2023 through 30 June 2023
ER -